Deep vein thrombosis future or investigational therapies
Ongoing Research
Phase 3 Trials
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer[1]
- Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
- Secondary Outcome Measures: Bleeding
- Estimated Enrollment: 2,430 patients
- Study Start Date: May 2008
- Estimated Study Completion Date: August 2012